This was as a result of the subgroup analysis (21) of BRCA1/2 mutant cancers (germline or somatic), in the molecularly unselected Study 19 of relapsed platinum sensitive high-grade serous ovarian cancer (22). This evidence concerns the gene BRCA1 and cancer.